Sanofi's $2.2B Acquisition of Inhibrx for Rare Disease Drug
TL;DR Summary
Sanofi is acquiring Inhibrx for $1.7 billion, primarily for its lead drug designed to treat alpha-1 antitrypsin deficiency (AATD) and plans to retain an 8% equity stake in the spun-out company New Inhibrx, while the other programs will be separated into this new entity.
- Sanofi to acquire Inhibrx for $1.7B Endpoints News
- France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 billion Reuters
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire
- Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal STAT
- Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs FierceBiotech
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
65%
125 → 44 words
Want the full story? Read the original article
Read on Endpoints News